We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Semiautomated Immunoassay for Post-Transplantation Immunosuppressant Assessed

By LabMedica International staff writers
Posted on 29 Apr 2014
Print article
Image: cobas e 411 immunoassay analyzers (Photo courtesy of Roche Diagnostics).
Image: cobas e 411 immunoassay analyzers (Photo courtesy of Roche Diagnostics).
Strategies to improve the long-term preservation of organ function and to reduce the incidence of accompanying diseases such as infections, renal insufficiency, cardiovascular disease and malignancy associated with immunosuppression are increasingly important.

Tacrolimus (TAC) is a post-transplantation immunosuppressant drug used in patients for whom careful monitoring of TAC concentration is essential and a new semiautomated immunoassay for TAC measurements is available and has been assessed in a multicenter evaluation.

A team of scientists from Klinikum-Stuttgart (Stuttgart, Germany) examined residual whole blood samples from patients undergoing TAC therapy after organ transplant and were used in assay evaluation at five clinical laboratories in Europe from October 2012 to April 2013. Studies included imprecision within-run and intermediate, functional sensitivity, linearity, and recovery from external quality assessment scheme (EQAS) samples. The assay was compared to liquid chromatography tandem mass spectrometry (LC–MS/MS) used routinely at each investigational site, and to another commercial immunoassay.

The team evaluated the Elecsys Tacrolimus immunoassay which was developed by developed by Roche Diagnostics for use on the cobas e immunoassay analyzers (Basel, Switzerland). The Elecsys Tacrolimus immunoassay uses the principle of electrochemiluminescence for detection and measurement. This assay was compared with in three centers to an immunoassay from Abbott Architect (Abbott Park, IL, USA) and in five centers to LC–MS/MS analysis.

The investigators observed linearity from 0.5 to 40 μg/L and determined a functional sensitivity of 0.3 μg/L. The within-run imprecision was less than 5.1% on cobas e 602 (5.1% at 1.5 μg/L) and less than 8.9% (8.9% at 0.8 μg/L) on cobas e 411. The intermediate imprecision for TAC concentrations equal to or greater than 6.8 μg/L was less than 6.5%. At lower therapeutic concentrations to 1.5 μg/L, it was consistently less than 10%.

The authors concluded that the assay performed well at all investigator sites, implementation and handling were simple, no deviation from the manufacturer insert information regarding calibration and or reagent stability was observed. The Elecsys Tacrolimus assay has good linearity, functional sensitivity and intermediate imprecision and is comparable to LC–MS/MS methods. The over-all performance of electrochemiluminescence immunoassay demonstrates a modern generation TAC assay that meets the demands of monitoring drug concentrations in current immunosuppressive regimens. The study was published on April 12, 2014, in the journal Clinical Biochemistry.

Related Links:
Klinikum-Stuttgart
Roche Diagnostics
Abbott 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.